Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.

Hazem AkkadNicola CaccianiMonica Llano-DiezRebeca Corpeno KalamgiTamara TchkoniaJames L KirklandLars Larsson

Published in: Acta physiologica (Oxford, England) (2018)

These results show that vamorolone provides a GC intervention superior to typical GCs in improving CIM outcomes. Further, the findings do not support the notion that moderate-dose GC treatment represents a factor triggering CIM.

Keyphrases

skeletal muscle
randomized controlled trial
adipose tissue
type diabetes
metabolic syndrome
mass spectrometry
high resolution
gas chromatography
replacement therapy
glycemic control
simultaneous determination